Olema director receives 29,500 stock options

Olema Pharmaceuticals director Andrew Rappaport received a new stock option grant as part of his compensation.

Rhea-AI Filing Summary

Olema Pharmaceuticals director Andrew Rappaport received a new stock option grant as part of his compensation. He was awarded options covering 29,500 shares of Olema common stock at an exercise price of $9.51 per share, held directly. The options expire on June 18, 2036.

The grant vests in 12 equal monthly installments starting June 18, 2026, as long as he continues to serve the company. If the options are not fully vested earlier, they vest in full on the date of Olema’s next annual stockholder meeting, again subject to continued service.

Insider Trade Summary

Grant/Award: 29,500 shares

Grant/Award 1 txn

Insider RAPPAPORT ANDREW

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	29,500	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 29,500 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 18, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

Key Figures

Option grant size: 29,500 options Exercise price: $9.51 per share Shares underlying options: 29,500 shares +3 more

6 metrics

Option grant size 29,500 options Stock Option (right to buy) awarded to director

Exercise price $9.51 per share Conversion or exercise price of stock option

Shares underlying options 29,500 shares Underlying Olema common stock

Expiration date June 18, 2036 Option term end date

Vesting start June 18, 2026 First of 12 monthly vesting installments

Post-transaction holdings 29,500 options Total options held following this grant

Key Terms

Stock Option (right to buy), exercise price, vest in a series of 12 successive equal monthly installments, annual meeting of stockholders, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 9.5100"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest in a series of 12 successive equal monthly installments financial

"The shares subject to the option vest in a series of 12 successive equal monthly installments"

annual meeting of stockholders regulatory

"Such shares vest in full on the date of the Issuer's next annual meeting of stockholders"

continuous service financial

"subject to the Reporting Person's continuous service through each applicable vesting date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Olema Pharmaceuticals (OLMA) director Andrew Rappaport receive in this Form 4 filing?

Andrew Rappaport received a grant of stock options for 29,500 shares of Olema common stock. These options are compensation-related, giving him the right to buy shares at a fixed exercise price over time if he remains in service.

What is the exercise price of Andrew Rappaport’s Olema (OLMA) stock options?

The stock options have an exercise price of $9.51 per share. This means he can buy Olema common stock at $9.51 per share once portions of the option vest, regardless of the market price at that time, while the options remain valid.

How many Olema (OLMA) shares are covered by Andrew Rappaport’s new stock option grant?

The new stock option grant covers 29,500 shares of Olema common stock. All 29,500 option shares are reported as directly held following the transaction, representing a single compensation award rather than multiple separate transactions.

How do Andrew Rappaport’s Olema (OLMA) stock options vest over time?

The options vest in 12 equal monthly installments starting on June 18, 2026, contingent on his continuous service. If any portion remains unvested by the issuer’s next annual stockholder meeting, that remainder vests in full on that meeting date, subject to continued service.

When do Andrew Rappaport’s Olema (OLMA) stock options expire?

The stock options expire on June 18, 2036. After this expiration date, any unexercised options become worthless, so exercises must occur before that date once the applicable tranches have vested under the grant terms.

Is Andrew Rappaport buying or selling Olema (OLMA) stock in this Form 4?

This Form 4 reports a grant of stock options, not an open-market buy or sale of shares. It is categorized as a grant or award acquisition, giving him the right to purchase shares in the future if vesting and exercise conditions are met.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/23/2026 - 05:22 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

RAPPAPORT ANDREW

(Last) (First) (Middle)

C/O OLEMA PHARMACEUTICALS, INC.

780 BRANNAN ST

(Street)

SAN FRANCISCO CALIFORNIA 94103

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Olema Pharmaceuticals, Inc. [ OLMA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$9.51	06/18/2026		A		29,500		(1)	06/18/2036	Common Stock	29,500	$0	29,500	D

Explanation of Responses:

1. The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 18, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

	/s/ Shawnte Mitchell, Attorney-in-Fact	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)